An Open-Label, Randomized, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 in Pediatric Subjects Aged 10 to Less Than 18 Years for the Treatment of Relapsing-Remitting Multiple Sclerosis, With Optional Open-Label Extension

drug protocol number
105MS306
drug sponsor
Biogen
drug study
Interferon beta-1a
drug trial site
KFSH&RC-J
drug status
Ongoing
drug phase